Joseph Tucker

Psychedelics biotech company Enveric Biosciences (NASDAQ:ENVB) completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and non-hallucinogenic N, N-Dimethyltryptamine (...

Psychedelics biotech company Enveric Biosciences (NASDAQ:ENVB) provided a corporate update and reported financial results for the third quarter ended Sept. 30, 2024. "The third quarter of 2024 was highlighted by important progress in the development of EB-003, our neuroplastogenic molecule that is...

Enveric Biosciences Inc (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogen therapeutics for mental health conditions, has entered into a licensing agreement with MycoMedica Life Sciences. Enveric will out-license its EVM201 program, including the drug candidate EB-002 (formerly...

Enveric Biosciences (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogenic small-molecule therapeutics, revealed positive data from preclinical safety and pharmacology studies of its lead drug candidate, EB-003. The Massachusetts-based company announced that the results show the...

Psychedelics have shown promise in treating various mental health issues, including PTSD and depression, but they’ve often faced notable challenges. Side effects like nausea, cardiovascular risks, and the potential for "bad trips" have raised concerns among both clinicians and patients. As...

Neuroplastogen biotech company Enveric Biosciences (NASDAQ:ENVB) has presented research highlighting its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit showing beneficial outcomes in preclinical models of anxiety and depression. EB-003 is a neuropathogenic and non-hallucinogenic N, N...

Psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental health disorders without the hallucinogenic effect...

Enveric Biosciences (NASDAQ:ENVB) reported it financial results on Wednesday for the first quarter of 2024 ended March 31, 2024. "We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug...

Psychedelics biotech firm, Enveric Biosciences (NASDAQ:ENVB) has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, British Columbia-based biopharma company MindBio Therapeutics Corp CSE: MBIO, which is pioneering novel treatments for psychiatric...

Enveric Biosciences (NASDAQ:ENVB), a Nasdaq-listed psychedelics biotech firm, has entered into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at treating breast cancer and other cancers. These methods utilize...

Enveric Biosciences (NASDAQ: ENVB) has completed manufacturing of drug material enabling the completion of preclinical work for EB-373 including all bioanalytical method validation, GLP toxicology and GLP safety pharmacology studies. Enveric will immediately commence remaining GLP studies to...

Enveric Biosciences (NASDAQ: ENVB) announced successful completion of preclinical absorption, distribution, metabolism, and excretion (ADME) and toxicology studies conforming to earlier positive results from pharmacokinetic (PK) animal studies and supportive of Enveric’s clinical design...

Enveric Biosciences (NASDAQ: ENVB) announced positive results from pharmacokinetic animal studies demonstrating oral bioavailability, rapid onset of action and systemic clearance, and a more favorable side effect profile for the company’s lead product candidate, EB-373. Pharmacokinetic...

Enveric Biosciences (NASDAQ: ENVB) announced the development of an improved formulation of EB-373 designed to enhance the drug product’s scalability, stability, and delivery for ongoing preclinical studies and planned clinical development. EB-373, Enveric’s lead product candidate, is a...